Home / WHO Europe HIV medication landscape

Interactive database

WHO Europe HIV Medication Access and Reimbursement Map

Explore the HIV medication landscape across 53 countries and areas of the WHO European Region, including Eastern Europe, the Caucasus and Central Asia. Choose a country to see every medicine, its status, and the source behind it.

53countries and areas
2,130country-product records
65%of verified records are reimbursed
739records still under review

Map

Fewer medicines reimbursedMore medicines reimbursedGrey: too few verified records

Share of verified records that are reimbursed. Select a country for medicine-level evidence.

Browse by country

CountryRecordsReimbursedNot reimbursedNot availableUnder reviewLast checked
Albania3861531414/09/2026
Andorra3820221414/09/2026
Armenia3850191414/09/2026
Austria4222221614/09/2026
Azerbaijan3850211214/09/2026
Belarus3853181214/09/2026
Belgium4229121002/11/2026
Bosnia and Herzegovina3861531414/09/2026
Bulgaria4219321814/09/2026
Croatia4223321402/11/2026
Cyprus4220221814/09/2026
Czechia4228221002/11/2026
Denmark4222221614/09/2026
Estonia4221321602/11/2026
Finland4222221614/09/2026
France423502502/11/2026
Georgia3850191414/09/2026
Germany4224021614/09/2026
Greece4220221814/09/2026
Hungary4224221402/11/2026
Iceland4220221814/09/2026
Ireland4222221614/09/2026
Israel3822021414/09/2026
Italy4224021614/09/2026
Kazakhstan3850211214/09/2026
Kyrgyzstan3850211214/09/2026
Latvia4222321502/11/2026
Lithuania4219321814/09/2026
Luxembourg4220221814/09/2026
Malta4220221814/09/2026
Monaco3820221414/09/2026
Montenegro3861531414/09/2026
Netherlands423322502/11/2026
North Macedonia3861531414/09/2026
Norway4222221602/11/2026
Poland423032714/09/2026
Portugal4222021814/09/2026
Republic of Moldova3850191414/09/2026
Romania4219321814/09/2026
Russian Federation3853181214/09/2026
San Marino3820221414/09/2026
Serbia3861531414/09/2026
Slovakia4219321814/09/2026
Slovenia4219321814/09/2026
Spain4223261102/11/2026
Sweden4222221614/09/2026
Switzerland382822602/11/2026
Tajikistan3850211214/09/2026
Turkey3818351214/09/2026
Turkmenistan3850211214/09/2026
Ukraine3850191414/09/2026
United Kingdom3825121002/11/2026
Uzbekistan3850211214/09/2026

How to read the data

Each record describes one medicine in one country or area. Marketing authorisation, national supply and reimbursement are separate measures; regional authorisation does not prove that a medicine is marketed, available or reimbursed in every country. Records under review are excluded from the reimbursed percentage and remain separately visible.

Status categories are an editorial comparison of the evidence stored for each country-product record. The database does not rank clinical quality, recommend treatment or infer national access from regional authorisation alone. Medicine availability, supply and reimbursement can change; records under review should not be read as confirmed access or non-access. This resource is for public information, research and policy discussion and is not prescribing guidance or medical advice.

If you identify an outdated record or can provide a current official source, please contact SHAPE so the database can be reviewed.